中东和非洲老年性黄斑变性 (AMD) 疾病市场，按类型（干性 AMD 和湿性 AMD）、最终用户（医院、专科诊所、门诊手术中心、家庭医疗保健和其他）、分销渠道（直接招标和零售销售）行业趋势和预测到 2029 年
市场分析和见解
中东和非洲与年龄有关的乳腺退化(AMD)疾病市场是由诸如老年人口增加、与年龄有关的乳腺退化(AMD)疾病发病率增加和管道产品增加其需求以及研发投资增加导致市场增长等因素驱动的。 目前,发达国家和新兴国家的保健支出已经增加,预计将为制造商开发新的创新产品创造竞争优势。
由于人口老化和预期寿命延长,与年龄有关的乳腺退化现象在发达国家的流行率预计将会增加。 据估计,近60%的病人在出生后不久患有严重的视力障碍。 这种疾病导致患者眼中中央视线模糊. 发达国家对与年龄有关的乳腺退化疾病治疗和诊断的需求有所增加。 然而,与治疗和程序有关的高成本以及严格的政府产品审批条例预计将会阻碍与年龄有关的乳腺退化(AMD)疾病市场的增长。
中东和非洲与年龄有关的乳腺退化(AMD)疾病市场是有利的,旨在减少疾病的发展。 数据桥市场研究分析认为,在2022至2029年的预测期间,中东和非洲与年龄有关的乳腺退化(AMD)疾病市场将以6.0%的CAGR增长.
|
报表计量 |
细节 |
|
预测期 |
2022至2029年统计 |
|
基准年 |
2021 |
|
历史年代 |
2020年(2019-2014年可定制). |
|
数量单位 |
收入(百万美元) |
|
覆盖部分 |
按类型(干线AMD和湿线AMD),终端用户(医院,专科诊所,门诊外科中心,家庭保健等),配送渠道(直接招标和零售销售),行业趋势和预测至2029年 |
|
涵盖国家 |
按国家(沙特阿拉伯、南非、阿联酋、以色列、科威特、埃及、中东其他地区和非洲)分列的2029年工业趋势和预测 |
|
覆盖的市场玩家 |
Novartis AG、Bayer AG、Johnson & Johnson服务公司、Adverum生物技术公司等 |
市场定义
与年龄有关的乳腺分泌(AMD)是一种眼疾,可以对控制尖锐和直立视力的眼部乳腺部分造成损害. 这导致中央视野模糊. 视线丧失可能由血管异常生长所引起. 有时异常的新血管会从胆固醇下和入出出出入出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出入出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出入出出入出出出出出出出入出出出出出入出出出出出出出入出出出出出出出出出出入出出出出出出出出出出出出出出出出入出出出出出出出出出出出出出出出出出入出出出出出出出出出出出出出出出入出出出出出出出出入出出出出出出出出入出出出出出出出出出出出出出出出出出出出出出出出出出 胆固醇(Choroid)是视网膜与外出,眼部坚固外衣(sclera)之间的血管层. 这些异常的血管可能会出出出液体或出血,干扰视网膜的功能. 男性衰老在老年人中很常见. 导致程序上升的其他原因可以由老年人人数不断增加的原因和对保健设施的要求来界定,包括在医疗需求最大的情况下对方便病人的诊断技术进行治疗,这可以进一步减轻保健设施的负担。
与年龄有关的乳腺分泌(AMD)疾病的诊断和治疗包括各种技术,这些技术允许在产品批准后对疾病进行诊断. 最近批准了该疾病的治疗,支持了市场的增长。 然而,这些治疗费用昂贵,并非所有病人都能得到。
中东和非洲与年龄有关的肿瘤衰竭(AMD)疾病市场动态
司机
- 老年人口增加
世界老年人口迅速增加。 随着年龄的增长,由于慢性病发病率的上升,老年病人的人数也相应增加。 年龄是任何疾病发展的一个严重风险因素,因为年龄是影响基本生物机制的基本参数。 因此,老龄化是中东和非洲早期AMD发病率的风险因素之一。 与年龄相关的乳腺退化(AMD)会给眼部的乳腺部分造成损害. 这导致中央视野模糊. 它可能造成不可逆的失明,是老年人视力受损的主要原因.
马氏衰老在老年人中更为常见. 诊断疾病在不同阶段是可能的,基因检测和视网膜成像的数量是检测疾病的一些技术. 对疾病的诊断主要通过光学成像技术和其他标准过程进行. 因此,老年人口的增加预计将推动中东和非洲与年龄有关的乳腺退化市场的增长。
- 与年龄有关的肿瘤衰老症发病率上升
发达国家对与年龄有关的乳腺退化疾病治疗和诊断的需求有所增加。 这些国家对与年龄有关的乳腺退化疾病市场以及遗传病的日益流行制定了补偿政策。
因此,这表明,与年龄有关的乳腺退化疾病(AMD)的日益流行预计将推动中东和非洲与年龄有关的乳腺退化疾病市场的增长。
机会
- 增加研究与发展
研究和开发是修改旨在治疗不同类型病人的治疗方法的先决条件。 全世界对与年龄有关的乳腺退化(AMD)治疗和程序的需求日益增加,涉及每一个中东和非洲国家。 正因为如此,这些公司继续注重研究和开发,以便在向病人和保健工作者提供有效治疗方面取得成功。
只能以某些方式来看待这些影响,包括疾病演变、视力逐渐受损、视网膜组织退化和遭受永久损害等有效的强大因素。
由于这些公司不断参与发展活动,市场上推出了更多的创新产品。 因此,这表明越来越多的研究与开发可望成为中东和非洲与年龄有关的乳腺退化疾病增长的一个机会。 全世界政府为了给人民提供最佳治疗而采取的各种方案和决定,是预期会增加需求的主要因素,并将为中东和非洲与年龄有关的乳腺退化疾病市场提供一个机会。
限制/挑战
- 高额审美手术程序
产品成本在市场上起重要作用。 在与年龄相关的乳腺分生(AMD)疾病中,一般观察到它们高度精密,需要精确,而其他规格则会提高产品的成本. 此外,与长期治疗有关的费用对于平均收入的人来说相当困难。 全世界对关键护理和重症监护单位服务的利用正在增加,而其昂贵的费用是目前保健系统的一个主要问题。
变性障碍患者通常需要长期治疗,并经常进行货币化和其他使用,从而消耗大量保健资源。 因此,大多数负担不起长期经济费用的病人在治疗的初始阶段就出院了. 但是,这增加了诊断中出现新并发症的可能性和易感性,这需要额外的保健资源和治疗。 由于创新和先进产品的成本很高,治疗成本按比例上升,因此,与年龄有关的乳腺退化(AMD)疾病治疗和诊断相关的高成本预计将限制中东和非洲与年龄有关的乳腺退化(AMD)疾病市场增长。
最近的事态发展
- 2022年1月,Genentech, Inc宣布美国食品药品管理局(FDA)批准Vabysmo(faricimab-svoa)治疗湿的AMD和DME. 这将有助于该公司在预测期间将产品商业化。
- 2022年4月,Graybug Vision Inc.宣布,公司在视觉和眼科研究协会(ARVO)的年度会议上为GB-401在初级开角青光眼(POAG)上展示了海报展示的临床前数据. 这将增加药品在市场上的安全和评价机会。
中东和非洲与年龄有关的肿瘤衰竭(AMD)疾病市场分裂
中东和非洲与年龄有关的乳腺退化(AMD)疾病市场分为三个值得注意的部分,这些部分基于类型、最终用户和分销渠道。 各部门之间的增长有助于你们分析一些特殊的增长领域和接近市场的战略,并确定你们的核心应用领域和目标市场的差异。
类型
- 干 AMD 设备
- 湿的AMD
根据类型,中东和非洲与年龄有关的乳腺退化(AMD)疾病市场被分入干燥的AMD和湿的AMD.
结束用户
- 医院
- 专科诊所
- 门诊中心
- 家庭保健
- 其他人员
在最终用户的基础上,中东和非洲与年龄有关的乳腺退化疾病市场分为医院、专科诊所、流动外科中心、家庭保健等。
分发频道
- 零售
- 直接招标
根据分销渠道,中东和非洲与年龄有关的乳腺退化(AMD)疾病市场被分割成零售和直接招标。
疾病市场区域分析/观察
分析与年龄有关的乳腺退化疾病市场,并按上述类型、最终用户和分销渠道提供市场规模的见解和趋势。
与年龄有关的乳腺退化(AMD)疾病报告所涵盖的国家是沙特阿拉伯、南非、阿联酋、以色列、科威特、埃及和中东其他地区以及非洲。
由于发展中地区的技术进步不断提高,南非预计将占据主导地位。
报告的国家部分还提供了影响市场的因素和影响市场当前和未来趋势的市场监管变化。 下游和上游价值链分析,技术趋势和搬运工的五种力分析等数据点,案例研究是用来预测个别国家市场情景的一些指针. 此外,还考虑了中东和非洲品牌的存在和可得性,以及它们由于来自当地和国内品牌的大规模或稀缺竞争而面临的挑战、国内关税和贸易路线的影响,同时对国家数据进行了预测分析。
竞争性景观和与年龄有关的男性衰老(AMD)疾病市场份额分析
中东和非洲与年龄有关的乳腺退化(AMD)疾病市场竞争情况提供了竞争者的详细信息。 详细情况包括:公司概况、公司财务、创收、市场潜力、研发投资、新市场举措、中东和非洲的存在、生产地点和设施、生产能力、公司优势和弱点、产品推出、产品宽度和广度以及应用优势。 上述数据点仅与公司关注与年龄有关的乳腺退化(AMD)疾病市场有关。
市场上的一些玩家有诺华AG,拜耳AG,约翰逊&约翰逊服务公司,阿德维鲁姆生物技术公司等.
研究方法
数据收集和基准年分析使用具有大样本规模的数据收集模块。 利用市场统计和连贯一致的模式分析和估计市场数据。 此外,市场份额分析和主要趋势分析是市场报告的主要成功因素. DBMR研究小组采用的关键研究方法是数据三角化,涉及数据挖掘、数据变量对市场的影响分析以及初级(工业专家)验证。 除此之外,数据模型包括供应商定位网格、市场时间线分析、市场概况和指南、公司定位网格、公司市场份额分析、计量标准、中东和非洲对区域和供应商份额分析。 如有进一步调查,请联系分析师。
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION
6.1.2 INCREASING GERIATRIC POPULATION
6.1.3 INCREASE IN PIPELINE PRODUCTS
6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS
6.2 RESTRAINTS
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 INCREASING RESEARCH AND DEVELOPMENT
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD)
6.4 CHALLENGES
6.4.1 LIMITED ACCESS TO TREATMENT
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS
7 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE
7.1 OVERVIEW
7.2 DRY AMD
7.3 WET AMD
7.3.1 MEDICATIONS
7.3.2 ANTI-VEGF THERAPY
7.3.3 GENE THERAPY
7.3.4 SURGERY
8 MIDDLE EAST & AFRICA AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 SPECIALTY CLINICS
8.4 AMBULATORY SURGICAL CENTERS
8.5 HOME HEALTHCARE
8.6 OTHERS
9 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 RETAIL SALES
9.2.1 HOSPITAL PHARMACIES
9.2.2 RETAIL PHARMACIES
9.2.3 OTHERS
9.3 DIRECT TENDER
10 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION
10.1 MIDDLE EAST & AFRICA
10.1.1 SOUTH AFRICA
10.1.2 SAUDI ARABIA
10.1.3 UAE
10.1.4 ISRAEL
10.1.5 EGYPT
10.1.6 KUWAIT
10.1.7 REST OF MIDDLE EAST & AFRICA
11 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 NOVARTIS AG
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENT
13.1.5.1 AGREEMENT
13.2 GENENTECH, INC.
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENT
13.3 BAYER AG
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENT
13.4 ADVERUM BIOTECHNOLOGIES, INC.
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENT
13.5 ASTELLAS PHARMA INC.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENT
13.6 GRAYBUG VISION INC.
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENT
13.7 GENSIGHT BIOLOGICS
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.7.4.1 EVENT
13.7.4.2 AWARD
13.8 IONIS PHARMACEUTICALS
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENT
13.8.4.1 EVENT
13.9 IVERIC BIO
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 JOHNSON &JOHNSON SERVICES, INC.
13.10.1 COMPANY SNAPSHOT
13.10.2 REVENUE ANALYSIS
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENT
13.10.4.1 COLLABORATION
13.11 KODIAK SCIENCES INC.
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
13.12 MEIRAGTX LIMITED
13.12.1 COMPANY SNAPSHOT
13.12.2 PRODUCT PORTFOLIO
13.12.3 RECENT DEVELOPMENTS
13.12.3.1 EVENTS
13.12.3.2 AWARD
13.12.3.3 COLLABORATION
13.13 OCUGEN INC.
13.13.1 COMPANY SNAPSHOT
13.13.2 PRODUCT PORTFOLIO
13.13.3 RECENT DEVELOPMENTS
13.13.3.1 INVESTMENT
13.13.3.2 CLINICAL TRIAL
13.14 PIXIUM VISION
13.14.1 COMPANY SNAPSHOT
13.14.2 REVENUE ANALYSIS
13.14.3 PRODUCT PORTFOLIO
13.14.4 RECENT DEVELOPMENT
13.14.4.1 AWARD
13.15 REGENXBIO INC.
13.15.1 COMPANY SNAPSHOT
13.15.2 PRODUCT PORTFOLIO
13.15.3 RECENT DEVELOPMENTS
13.15.3.1 EVENT
13.15.3.2 COLLABORATION
13.15.3.3 CERTIFICATION
14 QUESTIONNAIRE
15 RELATED REPORTS
表格列表
TABLE 1 VARIOUS EXAMPLES OF OPHTHALMIC DEVICES ARE SUMMARIZED IN THE BELOW-GIVEN TABLE ACCORDING TO THEIR CLASSIFICATION
TABLE 2 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 24 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 SOUTH AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 26 SOUTH AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 SOUTH AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 30 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 SAUDI ARABIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 SAUDI ARABIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 SAUDI ARABIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 36 UAE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 UAE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 UAE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 UAE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 40 UAE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 41 UAE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 ISRAEL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 ISRAEL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 46 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 47 ISRAEL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 48 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 EGYPT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 EGYPT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 EGYPT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 54 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 KUWAIT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 KUWAIT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 58 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 59 KUWAIT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 60 REST OF MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRY AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET
FIGURE 16 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2021
FIGURE 17 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2021
FIGURE 21 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 23 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 25 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 27 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SNAPSHOT (2021)
FIGURE 29 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2021)
FIGURE 30 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 31 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 32 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE (2022-2029)
FIGURE 33 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
